Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -79.38% is 77% below its 5-year average of -44.84%, near the low end of its 5-year range (-166.84%–161.54%).
290.68% below its 12-month average of 41.63%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -22.99%.
RETURN ON ASSETS (ROA)
-79.38%
RETURN ON ASSETS (ROA) AVG TTM
41.63%
RETURN ON ASSETS (ROA) AVG 3Y
-36.06%
RETURN ON ASSETS (ROA) AVG 5Y
-44.84%
RETURN ON ASSETS (ROA) AVG 10Y
-178.81%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-290.68%
CURRENT VS 3Y AVG
-120.15%
CURRENT VS 5Y AVG
-77.04%
CURRENT VS 10Y AVG
+55.61%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-146.03%
vs the sector median at left
Atara Biotherapeutics, Inc.
Market Cap
$87.85M
Return on Assets (ROA)
-79.38%
TTM Avg
41.63%
3Y Avg
-36.06%
5Y Avg
-44.84%
Market Cap
$87.96M
Return on Assets (ROA)
8.52%
TTM Avg
11.64%
3Y Avg
-8.81%
5Y Avg
-6.61%
Market Cap
$87.27M
Return on Assets (ROA)
-169.86%
TTM Avg
-100.47%
3Y Avg
-69.80%
5Y Avg
-64.10%
Market Cap
$89.44M
Return on Assets (ROA)
-86.56%
TTM Avg
-66.44%
3Y Avg
-84.84%
5Y Avg
-75.69%
Market Cap
$89.78M
Return on Assets (ROA)
-30.70%
TTM Avg
-50.88%
3Y Avg
-51.94%
5Y Avg
-48.05%
Market Cap
$85.86M
Return on Assets (ROA)
-91.66%
TTM Avg
-48.70%
3Y Avg
-37.97%
5Y Avg
-29.79%
Market Cap
$90.20M
Return on Assets (ROA)
1.69%
TTM Avg
-3.62%
3Y Avg
-6.49%
5Y Avg
-4.78%
Market Cap
$90.37M
Return on Assets (ROA)
-88.24%
TTM Avg
-139.34%
3Y Avg
-100.15%
5Y Avg
-71.92%
Market Cap
$90.64M
Return on Assets (ROA)
46.45%
TTM Avg
-49.63%
3Y Avg
-50.17%
5Y Avg
-40.85%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | $87.85M | -79.38% | 41.63% | -36.06% | -44.84% |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 8.52% | 11.64% | -8.81% | -6.61% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $87.27M | -169.86% | -100.47% | -69.80% | -64.10% |
| electroCore, Inc. (ECOR)vs › | $89.44M | -86.56% | -66.44% | -84.84% | -75.69% |
| Equillium, Inc. (EQ)vs › | $89.78M | -30.70% | -50.88% | -51.94% | -48.05% |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $85.86M | -91.66% | -48.70% | -37.97% | -29.79% |
| ImmuCell Corporation (ICCC)vs › | $90.20M | 1.69% | -3.62% | -6.49% | -4.78% |
| Biomea Fusion, Inc. (BMEA)vs › | $90.37M | -88.24% | -139.34% | -100.15% | -71.92% |
| Rallybio Corporation (RLYB)vs › | $90.64M | 46.45% | -49.63% | -50.17% | -40.85% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | -43.13% | -80.45% | -58.18% | -65.67% |
ROA
-79.4%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 161.54% |
| 2024-12-31 | -78.28% |
| 2023-12-31 | -166.84% |
| 2022-12-31 | -60.65% |
| 2021-12-31 | -72.66% |
| 2020-12-31 | -52.14% |
| 2019-12-31 | -84.85% |
| 2018-12-31 | -588.76% |
| 2017-12-31 | -548.68% |
| 2016-12-31 | -299.53% |
| 2015-12-31 | -176.08% |
| 2014-12-31 | -263.90% |
| 2013-12-31 | -169.27% |
| 2012-12-31 | -2874.13% |
